BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38464527)

  • 1. Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants.
    Chen L; He Y; Liu H; Shang Y; Guo G
    Front Immunol; 2024; 15():1339660. PubMed ID: 38464527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
    Xia S; Wang L; Zhu Y; Lu L; Jiang S
    Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
    Dhawan M; Saied AA; Mitra S; Alhumaydhi FA; Emran TB; Wilairatana P
    Biomed Pharmacother; 2022 Oct; 154():113522. PubMed ID: 36030585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
    Li Y; Shen Y; Zhang Y; Yan R
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.
    Alam MS
    Heliyon; 2023 Feb; 9(2):e13285. PubMed ID: 36744070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study.
    Aksenova AY; Likhachev IV; Grishin SY; Galzitskaya OV
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spike protein of SARS-CoV-2 Omicron variant: An
    Jimenez Ruiz JA; Lopez Ramirez C; Lopez-Campos JL
    Front Public Health; 2022; 10():1052241. PubMed ID: 36523581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
    Ao D; He X; Hong W; Wei X
    MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility.
    Boer JC; Pan Q; Holien JK; Nguyen TB; Ascher DB; Plebanski M
    Front Immunol; 2022; 13():954435. PubMed ID: 36569921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.